Advances in the study of NMDA receptors in depression pathogenesis and the antidepressant efficacy of their antagonists.
Asian journal of psychiatry – June 01, 2025
Source: PubMed
Summary
Breakthrough brain research reveals why traditional antidepressants can take weeks to work, while newer treatments targeting NMDA receptors can lift severe depression within hours. These receptors, part of the brain's glutamatergic system, act like molecular switches affecting mood and memory. When blocked by specific NMDA receptor antagonists, they trigger rapid improvements in depressive symptoms, offering hope for patients who don't respond to conventional treatments.
Abstract
N-methyl-D-aspartate receptors (NMDA receptors) play a crucial role as ionotropic glutamate receptors in regulating neuroplasticity, learning, memory, and a range of psychiatric disorders. Studies indicate that dysfunction of NMDA receptors is a key pathological mechanism in depression, where abnormal activation can result in neuronal excitotoxicity, excessive extracellular calcium ion accumulation, and disrupted neuroplasticity. As a non-competitive NMDA receptor antagonist, ketamine quickly relieves depressive symptoms by decreasing the activity of extracellular NMDA receptors and activating the mTOR signaling pathway. The treatment can improve severe depression and suicide thoughts within hours, but its potential for hallucinations, dissociative symptoms, and dependency restricts its broader application. Esketamine has demonstrated improvements in both side effects and efficacy and has received FDA approval, while other compounds with NMDA receptor modulating functions, such as memantine and rapastinel, are also showing potential in exploration. Future studies should concentrate on the molecular mechanisms of NMDA receptors, aiming to develop safer and more effective medications, and refine treatment strategies to offer personalized choices and longer-lasting efficacy for the treatment of depression.